ERBB2 and neoplasm: Successful retargeting has been demonstrated against a range of tumor-associated receptors, including IL13Rα2, uPAR, GFRα1, HER2, EGFR, PSMA, and EGFRvIII, enabling selective infection of various cancer cell types (Table 1).